Gliese A, Busch C-J, Knecht R
Klinik und Poliklinik für Hals-, Nasen- und Ohrenheilkunde, Kopf-Hals-Chirurgie und Onkologie, Universitäres Cancer Center Hamburg, Universitätsklinikum Hamburg-Eppendorf, Martinistraße 52, 20246, Hamburg, Deutschland.
HNO. 2016 Oct;64(10):717-22. doi: 10.1007/s00106-016-0243-6.
At the annual meeting of the American Society of Clinical Oncology (ASCO) 2016, results of current trials dealing with primary therapy for head and neck squamous cell carcinoma (HNSCC) were presented. Current trials investigate in particular therapy regimens for the treatment of locally advanced HNSCC. Concomitant chemoradiotherapy (CRT) remains the standard therapy approach. Current trials focus on sequential chemoradiation with modifications in induction chemotherapy (ICT) or the subsequent CRT schedule. Studies investigating the combination of targeted therapy with the epidermal growth factor receptor (EGFR) antibody cetuximab and concomitant, sequential, or adjuvant therapy were presented. The most important trials are summarized in this article.
在2016年美国临床肿瘤学会（ASCO）年会上，公布了有关头颈部鳞状细胞癌（HNSCC）主要治疗方法的当前试验结果。当前试验特别研究了局部晚期HNSCC的治疗方案。同步放化疗（CRT）仍然是标准治疗方法。当前试验集中于序贯放化疗，对诱导化疗（ICT）或后续CRT方案进行了调整。会上展示了研究靶向治疗与表皮生长因子受体（EGFR）抗体西妥昔单抗联合以及同步、序贯或辅助治疗的研究。本文总结了最重要的试验。
